MECP2 — Methyl-CpG Binding Protein 2

MECP2 — Methyl-CpG Binding Protein 2

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">MECP2 — Methyl-CpG Binding Protein 2</th>
</tr>
<tr> [@mecp2025]
<td class="label">Symbol</td> [@preclinical2024]
<td><strong>MECP2</strong></td> [@vashi2019]
</tr> [@lyst2013]
<tr> [@chahrour2008]
<td class="label">Full Name</td> [@ramocki2010]
<td>Methyl-CpG Binding Protein 2</td> [@ncbi]
</tr> [@omim]
<tr> [@allen]
<td class="label">Chromosome</td> [@allena]
<td>Xq28</td> [@allenb]
</tr> [@brainspan]
<tr> [@genes]
<td class="label">NCBI Gene</td> [@proteins]
<td><a href="https://www.ncbi.nlm.nih.gov/gene/4204" target="_blank">4204</a></td> [@bdnf]
</tr> [@httpswwwncbinlmnihgovgene]
<tr> [@httpsensemblorghomosapiensgenesummarygensg]
<td class="label">Ensembl</td> [@httpsomimorgentry]
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169057" target="_blank">ENSG00000169057</a></td> [@httpswwwuniprotorguniprotp]
</tr> [@mecp]
<tr> [@mecpa]
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/300005" target="_blank">300005</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P51608" target="_blank">P51608</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Rett Syndrome](/diseases/rett-syndrome), MECP2 Duplication Syndrome</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Cerebral cortex, Hippocampus, Cerebellum, Brainstem, Basal ganglia, Thalamus</td>
</tr>
<

MECP2 — Methyl-CpG Binding Protein 2

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">MECP2 — Methyl-CpG Binding Protein 2</th>
</tr>
<tr> [@mecp2025]
<td class="label">Symbol</td> [@preclinical2024]
<td><strong>MECP2</strong></td> [@vashi2019]
</tr> [@lyst2013]
<tr> [@chahrour2008]
<td class="label">Full Name</td> [@ramocki2010]
<td>Methyl-CpG Binding Protein 2</td> [@ncbi]
</tr> [@omim]
<tr> [@allen]
<td class="label">Chromosome</td> [@allena]
<td>Xq28</td> [@allenb]
</tr> [@brainspan]
<tr> [@genes]
<td class="label">NCBI Gene</td> [@proteins]
<td><a href="https://www.ncbi.nlm.nih.gov/gene/4204" target="_blank">4204</a></td> [@bdnf]
</tr> [@httpswwwncbinlmnihgovgene]
<tr> [@httpsensemblorghomosapiensgenesummarygensg]
<td class="label">Ensembl</td> [@httpsomimorgentry]
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169057" target="_blank">ENSG00000169057</a></td> [@httpswwwuniprotorguniprotp]
</tr> [@mecp]
<tr> [@mecpa]
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/300005" target="_blank">300005</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P51608" target="_blank">P51608</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Rett Syndrome](/diseases/rett-syndrome), MECP2 Duplication Syndrome</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Cerebral cortex, Hippocampus, Cerebellum, Brainstem, Basal ganglia, Thalamus</td>
</tr>
<tr>
<th class="infobox-subheader" colspan="2">Key Mutations</th>
</tr>
<tr>
<td colspan="2" style="font-size:0.85em">p.R106W — missense, MBD domain<br>p.R133C — missense, MBD domain<br>p.T158M — missense (most common)<br>p.R168X — nonsense, TRD domain<br>p.R255X — nonsense, TRD domain</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/depression" style="color:#ef9a9a">Depression</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">111 edges</a></td>
</tr>
</table>

MECP2 — Methyl-CpG Binding Protein 2

Introduction

Mecp2 — Methyl Cpg Binding Protein 2 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

MECP2 (Methyl-CpG Binding Protein 2) is a gene located on the X chromosome at Xq28 that encodes a critical epigenetic regulator of gene expression in the nervous system [@rett1999].
Mutations in MECP2 are the primary cause of [rett-syndrome](/diseases/rett-syndrome), a severe neurodevelopmental disorder affecting approximately 1 in 10,000–15,000 live female births worldwide [@rett2024].
The gene was first identified as a cause of Rett syndrome in 1999 by Ruthie Amir and colleagues in Huda Zoghbi's laboratory at Baylor College of Medicine [@rett1999].
MECP2 is catalogued as NCBI Gene ID [^4204] and OMIM [^300005].

The MeCP2 protein functions as both a transcriptional repressor and activator, binding to methylated CpG dinucleotides across the genome.
It is one of the most abundant chromatin-associated proteins in mature [neurons](/entities/neurons), approaching the abundance of histones, with approximately one molecule per every two nucleosomes [@birdseye2010].
Loss-of-function mutations lead to widespread dysregulation of gene expression programs essential for synaptic maturation, dendritic morphology, and neuronal circuit function.
Importantly, landmark studies have demonstrated that neurological deficits in Rett syndrome mouse models can be reversed by restoring MECP2 expression even in adult animals, providing strong rationale for therapeutic
gene replacement strategies [@reversal2007].

Gene Structure and Protein Domains

The MECP2 gene spans approximately 76 kb of genomic DNA and contains four exons, producing two major splice isoforms: MeCP2-e1 (encoded by exons 1, 3, 4) and MeCP2-e2 (encoded by exons 1, 2, 3, 4) [@mecp2025]. The MeCP2-e1 isoform is the predominant form in the brain and is preferentially affected in Rett syndrome.

The MeCP2 protein contains several functional domains:

• Methyl-CpG Binding Domain (MBD) — amino acids 78–162; binds methylated DNA at CpG and CpA dinucleotides with high affinity [@birdseye2010]
• Transcriptional Repression Domain (TRD) — amino acids 207–310; recruits the NCoR/SMRT co-repressor complex and histone deacetylases [@preclinical2024]
• NCoR/SMRT Interaction Domain (NID) — amino acids 285–309; critical for interaction with the NCoR/SMRT co-repressor complex; disruption of this domain alone is sufficient to cause Rett syndrome phenotypes [@preclinical2024]
• AT-hook motifs — two domains that bind AT-rich DNA sequences
• Intrinsically disordered regions — contribute to chromatin binding and phase separation properties

Normal Function

Epigenetic Regulation

MeCP2 is a master epigenetic regulator that reads [DNA methylation](/entities/dna-methylation) patterns and translates them into transcriptional outcomes.
In [neurons](/entities/neurons), MeCP2 binds broadly across the genome, preferentially at methylated CpG dinucleotides and non-CpG methylation sites (particularly mCA), which are highly abundant in mature [neurons](/entities/neurons) [@birdseye2010].
Through its interaction with the NCoR/SMRT co-repressor complex, MeCP2 modulates histone deacetylation and chromatin compaction [@preclinical2024].

MeCP2 functions as both a transcriptional repressor and activator: it represses genes enriched in methylated cytosine residues while activating genes through interaction with CREB1 and other transcriptional activators. This dual role explains why loss of MeCP2 leads to bidirectional dysregulation of gene expression — some genes are aberrantly upregulated while others are downregulated [@rett1999].

Neuronal Maturation and Synaptic Development

MeCP2 is essential for the maturation and maintenance of synapses and neuronal circuits. Key roles include:

• Dendritic morphology: MeCP2 regulates dendritic complexity, spine density, and spine morphology. Loss of MeCP2 results in reduced dendritic arborization and spine density [@rett2024]
• Synaptic transmission: MeCP2 modulates excitatory and inhibitory synaptic balance by regulating expression of genes encoding neurotransmitter receptors and synaptic scaffolding proteins
• Activity-dependent gene regulation: MeCP2 phosphorylation at S421 in response to neuronal activity releases MeCP2 from the [bdnf](/proteins/bdnf) promoter, allowing activity-dependent BDNF expression critical for [long-term-potentiation](/mechanisms/long-term-potentiation) [@mecp2025]
• RNA splicing: MeCP2 interacts with the splicing machinery and regulates alternative splicing of neuronal transcripts

Brain Expression

MeCP2 expression is ubiquitous but particularly high in the brain, where it increases dramatically during postnatal neuronal maturation. Key expression regions include:

• [cortex](/brain-regions/cortex) — particularly layers 2/3 and 5
• [hippocampus](/brain-regions/hippocampus) — CA1 and dentate gyrus
• [cerebellum](/brain-regions/cerebellum) — Purkinje cells and granule cells
• Brainstem — respiratory and autonomic nuclei
• [basal-ganglia](/brain-regions/basal-ganglia) — striatal neurons
• Thalamus — relay nuclei

Disease Associations

Rett Syndrome

[rett-syndrome](/diseases/rett-syndrome) is caused by loss-of-function mutations in MECP2 and is one of the most common genetic causes of intellectual disability in females [@rett1999][@rett2024].
The disorder follows an X-linked dominant inheritance pattern; affected males typically do not survive to birth, while heterozygous females exhibit symptoms due to mosaic X-inactivation patterns.
Clinical features include:

• Normal early development followed by developmental regression at 6–18 months
• Loss of purposeful hand skills replaced by stereotypic hand movements
• Loss of spoken language
• Gait abnormalities and ataxia
• Breathing irregularities (hyperventilation, breath-holding, apnea)
• Seizures (in ~80% of patients)
• Autonomic dysfunction
• Scoliosis and growth failure

MECP2 Duplication Syndrome

Genomic duplications encompassing MECP2 cause a distinct syndrome predominantly affecting males, characterized by severe intellectual disability, infantile hypotonia, progressive spasticity, epilepsy, recurrent respiratory infections, and premature death [@vashi2019]. This syndrome demonstrates that both too little and too much MeCP2 protein is detrimental to neuronal function.

Key Mutations

• p.T158M — the most common Rett syndrome mutation; disrupts MBD binding to methylated DNA
• p.R106W — missense in the MBD; moderate phenotype
• p.R133C — missense in the MBD; moderate phenotype with preserved ambulation
• p.R168X — early truncation removing TRD and NID; severe phenotype
• p.R255X — truncation within TRD; severe phenotype
• p.R270X — truncation within NID; severe phenotype
• p.R294X — late truncation preserving NID; milder phenotype
• p.R306C — missense disrupting NCoR/SMRT interaction; milder phenotype [@preclinical2024]

Therapeutic Approaches

Gene Therapy

Gene replacement therapy using adeno-associated viral (AAV) vectors to deliver functional MECP2 copies is a leading therapeutic strategy.
Multiple clinical trials are underway as of 2025, building on preclinical demonstrations that MeCP2 restoration can reverse neurological deficits in adult Rett syndrome mouse models [@reversal2007][@chahrour2008].
Key challenges include achieving appropriate expression levels (avoiding both under- and over-expression) and broad CNS distribution.

Reactivation of the Silent X Chromosome

Since Rett syndrome females carry one normal copy of MECP2 on their inactive X chromosome, therapeutic strategies to selectively reactivate this silenced copy represent an attractive approach. Several groups are investigating small molecules and antisense oligonucleotides targeting XIST or other regulators of X-inactivation [@mecp2025].

Other Approaches

• Read-through compounds for nonsense mutations (e.g., aminoglycosides, ataluren)
• Trofinetide (DAYBUE™) — FDA-approved in 2023; a synthetic analog of insulin-like growth factor 1 (IGF-1) tripeptide that modulates neuroinflammation and synaptic function
• [bdnf](/proteins/bdnf)-based therapies targeting downstream signaling deficits

Brain Atlas Resources

• [Allen Brain Atlas](https://brain-map.org)
• [Allen Human Brain Atlas: MECP2 search](https://human.brain-map.org/microarray/search/show?search_term=MECP2)
• [Allen Mouse Brain Atlas: MECP2 search](https://mouse.brain-map.org/search/index.html?query=MECP2)
• [Allen Cell Type Atlas](https://portal.brain-map.org/atlases-and-data/rnaseq)
• [BrainSpan Developmental Transcriptome](https://www.brainspan.org)

See Also

• [Index

External Links

• PubMed](https://pubmed.ncbi.nlm.nih.gov/)

Background

The study of Mecp2 — Methyl Cpg Binding Protein 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

Pathway Diagram

The following diagram shows the key molecular relationships involving mecp2 discovered through SciDEX knowledge graph analysis:

Pathway Diagram

The following diagram shows the key molecular relationships involving MECP2 — Methyl-CpG Binding Protein 2 discovered through SciDEX knowledge graph analysis: